Medical education at Leiden University Medical School. President & CEO of SQ Innovation (novel furosemide formulation for subcutaneous delivery). Founder of scPharmaceuticals (NASDAQ: SCPH). Founder of G3 Pharmaceuticals (galectin-3 inhibitors for cardiac and neurodegenerative disease). Co-Principal Investigator of the BioImage/BioImage-2 studies to identify novel methods to identify those at risk for major cardiovascular events. Career has spanned executive roles in global pharmaceutical companies and early-stage private and public pharmaceutical and device companies.

Jon Moore, PhD is a biochemist and cell biologist with 22 years of scientific leadership experience in industry, primarily in oncology. He is an Operating Partner at Advent Life Sciences where he co-founded both Epitopea and the remyelination start-up Pheno Therapeutics, serving both companies as their first CEO.

Prior to joining Advent, Dr Moore was CSO of gene editing tools and services company, Horizon Discovery, and Head of Biology at Vernalis Research. At both organisations his focus was on leading drug discovery projects, early-stage discovery collaborations and in and out-licensing key technologies.

Dr Moore also has extensive postdoctoral experience working with Tim Hunt at Cancer Research UK and Sally Kornbluth at Duke University. He holds a PhD from the University of Newcastle upon Tyne.

Ning Yu serves as Vice President, Device and Combination product development at Astria Therapeutics, responsible for the entire Device Lifecycle from early stages of research and development to late and commercial product development and manufacturing at Contract Development and Manufacturing Organizations (CDMOs).  Ning has 18 plus years of experience with medical devices and combination products, and worked in companies like Biogen, BD, Zimmer-Biomet. Ning has extensive experience with pen injector, prefilled syringe, autoinjector, on-body Injector, reconstitution kit,  ocular delivery system, implanted drug delivery device, connected device and smart packaging.  Ning holds a PhD in Mechanical Engineering from the University of Illinois Urbana-Champaign and MBA from Boston University.

Shawn is currently the Founder & CEO of the biotechnology startup Pendant Biosciences (formerly Nanoferix) an advanced biomaterials company developing innovative drug delivery technologies and surface coatings using a unique, polymer-based platform. The company is commercializing technology licensed from Vanderbilt University. Pendant is currently a Johnson & Johnson Innovations JLABS Resident Company.

Shawn recently received a Faculty appointment at the University of Louisville, School of Medicine, in the Department of Neurological Surgery & Neuroscience Research, as the Director of Innovation & Entrepreneurship. Shawn currently lectures on topics related to Entrepreneurship and startups. He’s currently a Mentor in Residence at Vanderbilt University in Nashville TN. 

Frank Walsh is the founder and CEO of Ossianix a privately held Biotechnology company that focuses on single domain VNAR antibodies with with a major interest in brain shuttles for Neurodegenerative diseases. Formerly, Frank was head of Discovery Research worldwide at Wyeth Pharmaceuticals in Collegeville, PA (2002-2009). Prior to joining Wyeth, he was SVP at GlaxoSmithKline UK and Head of the Neurology CEDD from 2000. From 1997-2000 he was VP of Neuroscience Research at Smith Kline Beecham UK. Before joining the pharmaceutical industry, Frank had a distinguished academic career in Neuroscience as the Sir William Dunn Professor of Experimental Pathology at London’s UMDS, Guy’s Hospital. He is the author of over 200 scientific publications and is a Fellow of the Royal Society of Edinburgh and the UK Academy of Medical Sciences.

Riet Dams leads the Global Pharmaceutical Product Development & Supply team within Johnson & Johnson Innovative Medicine’s Discovery, Product Development & Supply (DPDS) organization. She is responsible for shaping the strategic direction and providing oversight across a globally distributed team spanning the US, EU, and APAC regions. Her organization drives the development of innovative drug delivery solutions from early discovery through to commercialization, supporting the entire Synthetic Molecule Value Stream—including small molecules, oligonucleotides, peptides, and other complex bRo5 compounds. With over two decades of experience in pharmaceutical R&D, Riet has held both technical and leadership roles across several organizations, including MDS Pharma Services (UK), GlaxoSmithKline (Italy), and Aptuit (Italy). Since joining Johnson & Johnson in 2014, she has taken on progressively broader leadership roles in CMC development.

Riet holds a PhD in Pharmaceutical Sciences from Ghent University, completed in collaboration with the National Institutes of Health (USA), and is a trained pharmacist.

William Ferreira Andrén is the Founder & CEO of Aperya, a Stockholm-based biotech Startup developing a transdermal excipient that creates temporary micro-pores in the skin to enhance uptake of peptides, proteins, nucleic acids, and small molecules. The company’s Rolling Spiked Microspheres (Orbica) have shown up to 100× higher penetration in early studies.

William earned his MSc at KTH Royal Institute of Technology, with a thesis at Stanford University’s Dauskardt Lab, researching skin mechanics and transdermal drug delivery. Aperya is advancing a pre-clinical eczema program with the LEO Foundation and Karolinska Institute, while building partnerships across cosmetics, longevity, and pharma.

At PODD, he will highlight how excipient-based micropore technology enables topical delivery of biologics and small molecules.

Sruthi Ravindranathan, PhD is a Senior Scientist in Translational Medicine at Coherus Oncology, where she contributes to biomarker development for casdozokitug, the first and only clinical stage anti-IL27 antibody. Dr Ravindranathan brings over 10 years of experience in immuno-oncology drug development, with expertise spanning from target discovery through clinical translation. She has authored more than 15 scientific publications in high-impact journals including Nature Communications, holds four patents on novel cancer immunotherapies, and has presented at numerous international conferences. Dr Ravindranathan completed her postdoctoral fellowship at Emory University School of Medicine, where she developed novel immunotherapeutic strategies for solid tumors.

Jacek Lubelski, PhD is an accomplished biopharmaceutical leader, researcher and pharmaceutical developer specializing in gene and cell therapy and viral vector production. With over a decade-long career, he has made significant contributions to the development and advancement of gene therapy technologies, particularly in the field of recombinant adeno-associated virus (rAAV) therapeutics. Prior to joining NanoCell Therapeutics, Dr Lubelski served as the VP of Pharmaceutical Development at UniQure NV (NASDAQ: QURE), where he contributed to obtaining market authorization for Glybera, the first approved gene therapy medicine in the Western World, to treat lipoprotein lipase (LPL) deficiency. He has been instrumental in developing multiple rAAV-based translational advanced therapy medicinal products (ATMPs) to address challenging diseases like Haemophilia B, Sanphilipo B, and Acute Intermittent Porfyria. As Vice President of Development, Dr Lubelski also led vector development, process development, analytical methods, pre-clinical studies, and CMC activities focused on rAAV-based therapies. His expertise in leading complex teams across Europe and the USA has resulted in successful design and implementation of technological processes and analytical methods for viral vector manufacturing platforms.

In his current role as the Chief Technology Officer at NanoCell Therapeutics, Dr Lubelski spearheads all research and development activities. Beyond his leadership roles, he has played pivotal roles in collaborative projects with renowned institutions and organizations such as Synpromics and 4D Molecular Therapeutics, contributing to the development of improved promoters and capsids for human gene therapy. Dr. Lubelski was also selected as an expert by the European Directorate for the Quality of Medicines & Healthcare (EDQM) to contribute to the revision of gene therapy guidance, highlighting his deep knowledge, expertise, and contributions to shaping the future of gene therapies. He has coauthored more then 20 scientific publications as well as multiple patent applications pertaining to gene therapy filed.

Dr Lubelski holds a PhD in Molecular Microbiology from the University of Groningen and a Master's degree in Biotechnology from Maria Curie-Sklodowska University in Lublin, Poland. He is currently pursuing eMBA studies at the Rotterdam School of Management, Erasmus University in Rotterdam, the Netherlands.